Related Experiment Video

Updated: May 13, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Novel chemotherapies in development for management of castration-resistant prostate cancer

Alok K Tewari1, Daniel J George

  • 1Medical Scientist Training Program, Duke University Medical Center, Durham, NC 27705, USA.

Current Opinion in Urology
|March 21, 2013
PubMed
Abstract

Insights

New chemotherapies like epothilones show promise for castration-resistant prostate cancer (CRPC). Immunomodulators (IMiDs) are also under investigation, though their role requires further study in CRPC treatment.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Castration-resistant prostate cancer (CRPC) has limited treatment options.
  • Recent approvals offer new avenues, but further therapeutic strategies are needed.

Purpose of the Study:

  • To review novel chemotherapies, including epothilones and immunomodulators (IMiDs), in the context of CRPC treatment.
  • To summarize data on emerging agents within the evolving landscape of CRPC therapies.

Main Methods:

  • Review of phase II and III clinical trial data for epothilones (patupilone, sagopilone, ixabepilone) and IMiDs (lenalidamide, thalidomide).
  • Comparison of efficacy and safety data with established treatments like docetaxel.

Main Results:

  • Epothilones demonstrate comparable serum prostate-specific antigen response rates to docetaxel in phase II studies.
  • A phase III trial of lenalidamide plus docetaxel showed reduced overall survival versus docetaxel alone.
  • Ongoing trials are exploring lenalidamide in various combination regimens for CRPC.

Conclusions:

  • Epothilones may offer efficacy as an adjunct therapy for patients responding to docetaxel.
  • The role of IMiDs in CRPC, potentially in combination therapies, warrants further investigation.

More Related Videos

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...